Stay updated on Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the webpage content.
    Difference
    0.2%
    Check dated 2024-06-13T21:18:38.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the context of medical and healthcare-related publications and documentation.
    Difference
    0.2%
    Check dated 2024-06-06T14:25:16.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to a detailed description of eligibility criteria, explaining that researchers look for people who fit certain descriptions based on factors like general health condition or prior treatments. The new text also provides examples and directs users to read 'Learn About Studies' for more information.
    Difference
    21%
    Check dated 2024-05-22T21:17:34.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    2%
    Check dated 2024-04-30T22:55:13.000Z thumbnail image

Stay in the know with updates to Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Acalabrutinib in NSCLC Clinical Trial page.